The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
Journal article
Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902
Detection and Quantification of Antibody to SARS CoV 2 Receptor Binding Domain provides enhanced Sensitivity, Specificity and Utility.
Journal article
Rosadas C. et al, (2022), Journal of virological methods
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Journal article
Spencer AJ. et al, (2021), Nature Communications, 12
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies
Journal article
Spencer AJ. et al, (2021)
Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice.
Journal article
Collins KA. et al, (2021), Scientific reports, 11
A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice
Journal article
Silva-Cayetano A. et al, (2021), Med, 2, 243 - 262.e8
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Journal article
van Doremalen N. et al, (2021), Nature, 590, E24 - E24
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce robust immune responses in mice
Journal article
Spencer AJ. et al, (2021)
MAIT cell activation augments adenovirus vector vaccine immunogenicity
Journal article
Provine NM. et al, (2021), Science, 371, 521 - 526
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Journal article
Lambe T. et al, (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
Solar inactivated Salmonella Typhimurium induces an immune response in BALB/c mice
Journal article
Ssemakalu CC. et al, (2021), Heliyon, 7, e05903 - e05903
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
Journal article
Graham SP. et al, (2020), npj Vaccines, 5
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
Journal article
Rollier CS. et al, (2020), Scientific Reports, 10
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Journal article
van Doremalen N. et al, (2020), Nature, 586, 578 - 582